Please select the option that best describes you:
Topics:
Hematologic Malignancies • Radiation Oncology • Medical Oncology • Lymphoma • Non-Hodgkin Lymphoma • ASTRO 2025
What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?
Should the reduced dose be adopted for all, or would you reserve this approach for specific patient subgroups?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Clinical Trials Session Presentation "Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group" by Dr. Christopher Kelsey.
Answer from: Radiation Oncologist at Academic Institution
The primary endpoint of the study was 5-year local control. The study was powered to estimate this endpoint after the last patient had at least 2 years of potential follow-up (which will be reported at ASTRO). Local failures after 2 years are uncommon. The estimated 5-year freedom from local recurre...
Sign in or Register to read more